Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / PYX - 4 Healthcare Stocks Looking To Set February Highs


PYX - 4 Healthcare Stocks Looking To Set February Highs

CORAL GABLES, FL / ACCESSWIRE / February 12, 2019 / The healthcare stock market's success is intrinsically connected to victories of companies working in the healthcare industry. Now, more than ever, consumers are insistent that companies take their needs into consideration when designing new products and services. As it relates to the field of medicine, the expression of these needs is crucial because a company being able to meet such demands translates to improving the quality of life for individuals suffering from a spectrum of diseases. With the advent of new medical technologies and an influx of doctors considering alternative forms of treatment previously thought to be ineffective, the healthcare industry is buzzing with excitement. If the healthcare sector continues to operate with the patient's best interest at heart, companies in the space may see investors paying closer attention in the near future. Premier Health Group (OTC: PHGRF) (CSE: PHGI), Aurora Cannabis Inc (NYSE: ACB, TSX: ACB), Pyxus International Inc (NYSE: PYX), and Proteon Therapeutics Inc (NASDAQ: PRTO) represent four healthcare companies operating with the consumer's best interests in mind.

Premier Health Group (OTC: PHGRF) (CSE: PHGI) is a company focused on developing innovative approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network. Whereas other companies have seemingly hit a brick wall, Premier continues to prove that innovation is deeply embedded in the company's core framework.

Premier Health Group (OTC: PHGRF) (CSE: PHGI) announced towards the end of last week that the Company is now formally entering the cannabis clinic space. Premier's recent acquisition of Cloud Practice Inc has provided an underlying platform to help empower and streamline patient-doctor interaction. Whereas other clinics typically struggle with the labor-intensive process of onboarding patients, this will be done automatically with Premier's smart EMR.

Premier Health Group (OTC: PHGRF) (CSE: PHGI)'s integrated technology will assess the patient's data, and through the use of analytics, output a comprehensive recommendation along with links to corresponding research relevant to the diagnosis. The only responsibility of the healthcare professional is that they must simply determine which patient could best be served by using medical cannabis products.

Dr. Essam Hamza, CEO of Premier Health Group (OTC: PHGRF) (CSE: PHGI), commented, "We are currently working on a partnership model to hard code the decision-making process into the Electronic Medical Records (EMR). There has been a critical gap between the patient's need for medical cannabis and the doctor's knowledge and comfort level in prescribing it. At Premier we understand the frustration felt from both the patient and the doctor and are integrating what we think is a revolutionary process. This new tool will allow us to provide a much-needed service to the 287 clinics and almost 3 million patients in our ecosystem."

For More Information On Premier Health Group, Click Here

Aurora Cannabis Inc (ACB), one of the leading producers of cannabis for the medicinal marijuana sub-sect of the industry, today announced that the Company's construction of a 300,000 square foot expansion at the Edmonton International Airport is going as planned. The new facility, named Aurora Polaris, is intended to serve as Aurora's center of excellence for the industrial-scale production of higher margin, value-added products, such as edibles which Health Canada regulations propose to permit from October 2019 onwards.

Terry Booth, CEO of Aurora, said, "our product development team has a built a deep and exciting pipeline of new high-value products, and we look forward to servicing our markets with the next generation of cannabis innovations. We intend to integrate Polaris with operations at Aurora Mountain, Aurora Sky and Aurora Sun, generating operational efficiencies and hard to imitate vertical integration synergies."

For More Information on Aurora Cannabis Inc, Click Here

Pyxus International Inc (PYX), a global value-added agricultural company invested in the future of cannabis and its potential health-focused benefits, announced results for its third quarter ended December 31, 2018, on Monday. Per the results, Sales and other operating revenues increased 9.8% to $524.5 million primarily due to higher volume in Africa attributable to larger crop sizes.

Following the announcement, Pieter Sikkel, President and CEO of Pyxus, said, "it has been one year since we announced our 'One Tomorrow' transformation plan, in which we revealed our pursuit of future growth opportunities and commitment to reshaping our brand as the trusted provider of responsibly produced, independently verified, sustainable, and traceable agricultural products and services."

For More Information On Pyxus International Inc, Click Here

Proteon Therapeutics Inc (PRTO), a company developing novel pharmaceuticals to address the medical needs of patients with kidney and vascular ailments, announced earlier this month the publication in the Journal of Vascular Surgery of results from its Phase 3 PATENCY-1 clinical trial of investigational vonapanitase. Per the results, the trial showed a 34% reduction in the risk of secondary patency loss over one year, compared to placebo (p=0.048).

In a press release regarding the announcement, Anthony J. Bleyer, lead author of the publication, commented, "the PATENCY-1 results are promising because of the improvement in fistula use and secondary patency, two clinically meaningful endpoints for patients, their families, and their physicians. I look forward to the results of the ongoing PATENCY-2 trial, in which fistula use and secondary patency are the co-primary endpoints."

For More Information On Proteon Therapeutics Inc, Click Here

What Is Stock Price (StockPrice.com)?

Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.

StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.

At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 — 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid "500,000" shares of restricted common shares (as of 1/2/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.

Contact Information:

news@stockprice.com

SOURCE: StockPrice.com

Stock Information

Company Name: Pyxus International Inc.
Stock Symbol: PYX
Market: NYSE

Menu

PYX PYX Quote PYX Short PYX News PYX Articles PYX Message Board
Get PYX Alerts

News, Short Squeeze, Breakout and More Instantly...